Notch signaling in cancer: Complexity and challenges on the path to clinical translation
- PMID: 33862222
- DOI: 10.1016/j.semcancer.2021.04.008
Notch signaling in cancer: Complexity and challenges on the path to clinical translation
Abstract
Notch receptors participate in a conserved pathway in which ligands expressed on neighboring cells trigger a series of proteolytic cleavages that allow the intracellular portion of the receptor to travel to the nucleus and form a short-lived transcription complex that turns on target gene expression. The directness and seeming simplicity of this signaling mechanism belies the complexity of the outcomes of Notch signaling in normal cells, which are highly context and dosage dependent. This complexity is reflected in the diverse roles of Notch in cancers of various types, in which Notch may be oncogenic or tumor suppressive and may have a wide spectrum of effects on tumor cells and stromal elements. This review provides an overview of the roles of Notch in cancer and discusses challenges to clinical translation of Notch targeting agents as well as approaches that may overcome these hurdles.
Keywords: Cancer; Notch; Oncogene; Signaling; Tumor suppressor.
Copyright © 2021 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest Jon C. Aster is a consultant for Ayala Pharmaceuticals and Cellestia, Inc., companies that are developing Notch pathway inhibitors for clinical use. He does not hold an equity position in either company. Antonio Ferreira declares that he has no conflicts of interest.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
